Periodic Reporting for period 1 - ArtOfHeart (The first Total Artificial Heart (TAH) that truly mimics the human heart and has the potential to revolutionise the market)
Reporting period: 2022-04-01 to 2023-09-30
In vivo results are similar to those achieved by market competitors prior to them initiating clinical trials. Work is ongoing to optimise animal care protocol as this is complicated and has been identified to be a unique area of expertise held by a small group of individuals in the world (and outside of Europe).
In vitro human blood hemolysis testing against the current market-leading device in a more advanced test rig that mimics full body circulation achieved.
A collaboration with Swedish start-up company InvivoPower was initiated since they received grant funding from Vinnova. This resulted in the first proof-of-concept of wireless energy transfer via the skin for our RTS system.
The work on the electronic architecture of the RTS system is expected to result in a thin, flexible power cable (driveline through the skin). This could translate to reduced infection risk in the patient compared to solutions in current clinical use.
The first proof-of-concept of wireless energy transfer via the skin for our RTS system is expected to result in reduced infection risk in the patients.